Historical record - last NADAC effective date: 6/22/2022
Product Information
QSYMIA 3.75 MG-23 MG CAPSULE is a brand product labeled by Vivus LLC, priced at $5.7651 per EA under NDC 62541020130. Its NADAC has been published 442 times since Dec 18, 2013.
FDA first approved this application on Jul 17, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3.75; 23 mg/1; mg/1
Manufacturer
Vivus LLCNDC
62541020130
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
6/22/2022
Active Ingredients
PHENTERMINE HYDROCHLORIDE; TOPIRAMATEApproval Type
New Drug (NDA)
FDA Application
NDA022580FDA Approved
7/17/2012
TE Code
AB
On Market Since
9/17/2012
Pharmacological Classes
Price Statistics
The NADAC for QSYMIA 3.75 MG-23 MG CAPSULE has been published 442 times since Dec 18, 2013, and over the history we have for it it has risen 31.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.7651 per EA |
|---|---|
| All-time high | $5.9301 (Apr 13, 2016) |
| All-time low | $4.3663 (Jan 22, 2014) |
| Median price | $5.7651 |
| Average price | $5.6306 |
| Largest weekly change | +11.0% (Apr 9, 2014) |
| Weeks tracked | 442 |
| Tracking since | Dec 18, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
-0.2%
All
+31.9%
Last surveyed Dec 28, 2022 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 48% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vivus LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
phentermine and topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QSYMIA 3.75 MG-23 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for QSYMIA 3.75 MG-23 MG CAPSULE, manufactured by Vivus LLC, is $5.7651 per EA (NDC 62541020130), effective Dec 28, 2022.
How has the price of QSYMIA 3.75 MG-23 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for QSYMIA 3.75 MG-23 MG CAPSULE has risen 31.9%. It has been tracked across 442 weekly CMS publications since Dec 18, 2013.
What are the highest and lowest recorded NADAC prices for QSYMIA 3.75 MG-23 MG CAPSULE?
Since Dec 18, 2013, the NADAC for QSYMIA 3.75 MG-23 MG CAPSULE has ranged from a low of $4.3663 (Jan 22, 2014) to a high of $5.9301 (Apr 13, 2016), with a median of $5.7651 per EA.
Are there cheaper alternatives to QSYMIA 3.75 MG-23 MG CAPSULE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE, is $2.9858 per EA — about 48% below QSYMIA 3.75 MG-23 MG CAPSULE.
Who manufactures QSYMIA 3.75 MG-23 MG CAPSULE?
QSYMIA 3.75 MG-23 MG CAPSULE (NDC 62541020130) is labeled by Vivus LLC, and CMS classifies it as a brand product.